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INTRODUCTION
In type 2 diabetes mellitus (DM), lipid-lowering therapy is
one of the most important cares together with blood glucose
and blood pressure control (1). The Adult Treatment Panel III
(ATP III) guidelines of the National Cholesterol Education
Program (NCEP) extend the population that is believed to
benefit from cholesterol reduction by adding patients with
DM to the secondary prevention group (2). The target goal of
lipid control in type 2 DM became stricter and the percentage
of patients achieved the target goal got to be less satisfactory. 
Guidelines recommended that lipid profiles would be best
obtained in the fasting state. The American Diabetes Associa-
tion (ADA) recommended to measure fasting lipid profile at
least once a year for screening of dyslipidemia in most diabetics
(1). However, only 50% of all patients have their lipid test
result annually (3-5). The ATP III of NCEP guidelines men-
tioned about measuring cholesterol in the nonfasting state. The
guideline states, ‘‘If the testing opportunity is nonfasting, only
the values for total cholesterol (TC) and high density lipopro-
tein (HDL) cholesterol will be usable’’ (2). Most patients in
medical offices are in the nonfasting state. Fasting is much
uncomfortable in diabetics because of the fear of both hyper-
glycemia and hypoglycemia. This may limit lipid profile test,
thus decrease the number of patients who were prescribed drug
therapy. As a result, percentage of patients who arrived the
goal levels of lipid was lowered. Instead of rescheduling the
patient for fasting levels, testing nonfasting lipid might im-
prove doctor and patient compliance with ATP III guidelines. 
There are several studies showing that nonfasting total cho-
lesterol, HDL cholesterol, and low-density lipoprotein (LDL)
cholesterol levels can identify most of patients who did not
meet the goal of cholesterol levels (6-9). However, other stud-
ies showed that nonfasting levels were significantly different
from fasting levels (10). All of previous studies were performed
for Western diet and some of them were not conducted with
standardized meal. In addition, few reports studied fasting
and post-prandial lipid profile with statin treatment in dia-
betes patients. In this study, we tried to compare the fasting
and post-prandial lipid profiles in type 2 DM with statin treat-
ment under traditional Korean diet. 
MATERIALS AND METHODS
Subjects and methods
Our subjects were clinically stable type 2 diabetes patients
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It is inconvenient to perform serum lipid analysis in fasting state in diabetic patients
with drug treatment. In patients with statin treatment and Asian diet, it has not been
clearly known whether non-fasting values could be used for the clinical decision mak-
ing in diabetic patients. In this study, fasting and post-prandial plasma lipid profiles
of hospitalized type 2 diabetic patients taking statin, were measured in whom stan-
dard diabetic breakfast in traditional Korean style were provided. In repeated-mea-
sures ANOVA, there were no significant differences among fasting, post-prandial
2 and 4 hr low-density lipoprotein (LDL) and high density lipoprotein (HDL) choles-
terol values. When compared to fasting levels, both post-prandial 2 hr and 4 hr LDL
cholesterol levels were misclassified as not achieved target goal only in 4% of pati-
ents. Post-prandial HDL cholesterol matched with fasting values in women, without
exception. In conclusion, the fasting and post-prandial LDL and HDL cholesterol
levels are not significantly different each other and can be used in the assessment
of achieving target goal in type 2 diabetes taking statin after Korean diet. 
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taking statins at least for previous 3 months and their other
medications have not been changed during the last 3 months.
Patients with a history of severe hypoglycemia, severe hyper-
glycemia, bleeding disorder, liver diseases, renal insufficien-
cy (serum creatinine >1.5 mg/dL), malnutrition, and preg-
nant and lactating women were excluded. 
Subjects were admitted to Maryknoll Medical Center. Fol-
lowing an overnight fast of at least 10 hr, fasting venous blood
samples were obtained. Subjects were then provided with a
standard diabetic diet. They finished their meal within 30 min.
Venous blood was sampled at 2 hr and 4 hr following a stan-
dard breakfast. This study was approved by the Institution-
al Review Boards of Maryknoll Medical Center, and written
informed consent was obtained from each patient.
Serum levels of total cholesterol, HDL cholesterol, LDL
cholesterol, and triglycerides were measured enzymatically
with a Hitachi 7600-020 (Hitachi Co., Tokyo, Japan) auto-
matic analyzer, with coefficients of variation of 1.2% for cho-
lesterol and 1.9% for triglycerides.
Statistical analysis
Statistical analyses were performed with the SPSS software,
version 15.0 (SPSS Inc., Chicago, IL, USA). Repeated mea-
sured t tests were used to determine if differences in fasting
and nonfasting measurements for total cholesterol, LDL choles-
terol, HDL cholesterol and triglyceride were statistically sig-
nificant. 
We adopted the ATP III guideline for diabetes to assess if
they meet the treatment goal. The target of LDL cholesterol
for patients with diabetes was set at <100 mg/dL (2.59 mM/
L) and the non- HDL cholesterol target was <130 mg/dL
(3.36 mM/L). The HDL cholesterol goal for diabetic women
and men were >50 mg/dL (1.3 mM/L) and >40 mg/dL (1.04
mM/L), respectively. The agreements between the fasting and
post-prandial 2 hr or 4 hr values for each goal were assessed
by sensitivity, specificity and McNemar test.
RESULTS 
Characteristics of subjects and diet
The number of participants was 35, and 60% of them were
women. Their mean age was 57.8±9.9 yr and mean body
mass index (BMI) was 24.3±3.5 kg/m2. Mean known dia-
betic duration was 10.1±7.4 yr and their mean HbA1c was
7.8±1.6% (Table 1). Their standardized diabetic breakfast
was provided by Korean traditional style including steamed
rice and several side dishes. Their mean total calories were
supposed to be 1,778.6±298.1 kcal and mean calories of
breakfast was 520±52 kcal, composed by 20% of protein,
20% of fat and 60% of carbohydrate. 
Fasting and post-prandial lipid values 
The levels of total cholesterol after meal were increased com-
pared to fasting total cholesterol values, and their changes were
statistically significant (Pvalue <0.05) (Fig. 1, Table 2). Post-
prandial LDL cholesterol levels were slightly lower than fast-
ing values but did not show any statistical significance. The
significant changes in HDL cholesterol after standard break-
fast were not observed in our study. The levels of triglyceride
at post-prandial 2 hr and post-prandial 4 hr were significantly
higher than fasting tirglyceride value (Pvalue <0.05). Triglyc-
eride levels were highest at post-prandial 4 hr, 23.4% higher
than the fasting levels (Fig. 1, Table 2). 
Attainment of target lipid values
We adopted the ATP III guideline to compare the num-
ber and the percentages of patients who achieve their target
goal between fasting and post-prandial lipid levels. The tar-
get of LDL cholesterol for patients with diabetes is less than
100 mg/dL (2.59 mM/L). Twenty seven out of 35 patients
met the LDL cholesterol treatment goal in post-prandial 2 hr
LDL cholesterol level (Table 3). Among them, 96% had LDL
cholesterol level less than 100 mg/dL in fasting state. In terms
of post-prandial 4 hr values, our study showed the same results.
Both post-prandial 2 hr and 4 hr LDL cholesterol values were
87.5% sensitive and 96.3% specific. We set a goal in HDL
BMI, body mass index; DM, diabetes mellitus.
Characteristics Mean values±SD
Gender: M/F (number) 14/21
Age (yr) 57.8±9.9
BMI (kg/m
2) 24.3±3.5
DM duration (yr) 10.1±7.4
HbA1c (%) 7.8±1.6
Energy of breakfast (kcal) 520±52 
Carbohydrate (% of energy) 60
Total fat (% of energy) 20
Protein (% of energy) 20
Table 1. Baseline characteristics and dietary intake of the study
subjects
Data are presented as mean value±SD.  
*P<0.05 compared to fasting value by repeated measure test.
LDL, low-density lipoprotein; HDL, high density lipoprotein.
Lipoproteins Fasting PP2 hr PP4 hr
Total cholesterol* (mg/dL) 150.1±37.4 152.8±36.1 154.23±39.1
LDL cholesterol (mg/dL) 83.6±28.1 82.8±26.0 82.9±27.1
HDL cholesterol (mg/dL) 40.5±12.8 40.3±11.8 40.6±12.9
Triglyceride (mg/dL) 122.7±54.1 137.0±74.1* 151.4±89.9*
Table 2. Mean values of fasting and post-prandial (PP) lipopro-
teinsPost-Prandial Lipid Levels in Diabetes with Statin 389
cholesterol for women as >50 mg/dL (1.3 mM/L). In our study,
the patients achieving goal at post-prandial 2 hr and 4 hr HDL
cholesterol levels were perfectly matched to fasting (Table 4).
Compared to fasting HDL cholesterol levels in men, pp 2 hr
and 4 hr levels were misclassified as achieved target goal in
22% and 12%, respectively (Table 4). For identifying women
with low fasting levels of HDL cholesterol, post-prandial 2 hr
and 4 hr HDL cholesterol values were all 100% sensitive and
specific. In men, the sensitivity and specificity of post-pran-
dial 2 hr HDL cholesterol values were 77.8% and 87.5%,
respectively. In case of post-prandial 4 hr HDL cholesterol,
both sensitivity and specificity were 100%. Fourteen % of
subjects with elevated non-HDL cholesterol levels would be
false negative if post-prandial 2 hr non-HDL cholesterol esti-
mates were used for assessing target goal. When we use 4 hr
post-prandial non-HDL cholesterol, false negative was 7%
of patients (Table 5).
DISCUSSION
The lowering LDL cholesterol levels in individuals with and
without pre-existing coronary heart disease has been shown
to reduce cardiovascular event and total mortality (11-15).
However, despite the widespread use of statins during the
last decade, recent studies have shown that about 60-70%
of patients do not arrive the goal (16-20). The failure of achiev-
ing target has been related to a number of factors, including
Fig. 1. Changes in fasting and post-prandial 2- and 4-hr lipid values. (A) total cholesterol, (B) triglyceride, (C) LDL cholesterol, (D) HDL
cholesterol. 
*P<0.05 compared to fasting value by repeated measure test.
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The unit of LDL cholesterol is mg/dL. 100 mg/dL=2.6 mM/L.
P value was calculated by McNemar test.
LDL, low-density lipoprotein; NS, not significant.  
Concentration 
of LDL-C
Fasting
Number 
P
value LDL-C <100
Number (%)
LDL-C ≥100
Number (%)
PP 2 hr
<100 27 26 (96) 1 (4)
≥100 8 1 (12) 7 (88) NS
PP 4 hr
<100 27 26 (96) 1 (4)
≥100 8 1 (12) 7 (88) NS
Table 3. Comparison of achieving of target goal between fast-
ing, post-prandial (PP) 2 and 4 hr LDL cholesterol (LDL-C)390 M. Kim, J. Suk, H. Kim, et al.
insufficient pharmacological effect at the starting dose of a
statin and a subsequent lack of willingness to escalate statin
dose. One study reported that only 33% of patients had test-
ed lipid levels (21). And the situation has not been improved
over the years. Only 40% coronary disease patients knew cur-
rent lipid values (22). They suggested that the fact they don’t
have recent lipid result might be another reason for not attain-
ment of lipid goal. Most people visit their doctor in nonfast-
ing state and if they are diabetic patients, it is not easy to keep
them fasting because of hypoglycemic risk. In order to obtain
fasting lipid results, we have to reschedule the patient to per-
form fasting level test and let them take a risk of hypogly-
cemia and hyperglycemia. If nonfasting lipid are tested, doc-
tor and patient compliance with ATP III guidelines might
be improved and more people may reach the goal. 
The results of present study showed that nonfasting LDL
and HDL cholesterol levels were not different from fasting
levels in type 2 diabetes patients with Korean diet and tak-
ing statins. Other recent study showed that fasting and non-
fasting LDL cholesterol levels were not significantly different
in type 2 DM (10). Several reports showed nonfasting LDL
cholesterol level were significantly different to fasting one
(6-9). But their study protocol was different. They provided
Western diet. They used a fat rich diet which was consisted
of 880 calories and 57% of calories from fat (7, 10) or usual
Western breakfast which was consisted of 500 calories, 40%
from fat and 44% from carbohydrate (9). Compared to west-
ern diet, traditional Korean diet has lower fat percentage out of
total calories. The amount of fat in diet can influence plasma
LDL and HDL cholesterol level (23-25). Atorvastatin reduc-
ed mean changes in LDL and HDL cholesterol after meal (8).
Those studies may be explanations why our study did not
show any significant differences between fasting and nonfast-
ing LDL and HDL cholesterol. 
For detecting patients who attain target LDL and HDL
cholesterol levels, the both post-prandial 2 hr and 4 hr LDL
cholesterol levels misclassified only 4% of patients and none
in case of post-prandial HDL cholesterol. We may suggest
we can keep our treatment without further action if nonfast-
ing LDL cholesterol and HDL cholesterol levels meet the goal.
When we compared the patients who did not achieve goal in
post-prandial 2 hr and 4 hr levels to fasting LDL cholesterol
levels, 12% of patients were false positive. Even if we increase
the dose of statin to attain target goal using post-prandial LDL
cholesterol level, more patients meet the goal and have more
benefit evidenced by previous large studies. Nonfasting HDL
cholesterol levels were matched perfectly to fasting level in
women and showed 12-22% false positive in men. In real
clinical practice, checking post-prandial LDL and HLD choles-
terol level may save our money and time and increase com-
pliance of patients and doctor. 
One study showed that lower fasting and post-prandial lev-
els of plasma total, LDL and non-HDL cholesterol during
metformin versus repaglinide treatment in type 2 DM (26).
We did not compare the effect of oral hypoglycemic agents
on cholesterol level because the number of our subjects was
so small. In order to minimize the effect of various medica-
tions, we selected our subjects who had kept their treatment
without any change at least for 3 months.
It is concluded that post-prandial LDL and HDL choles-
The unit of non HDL cholesterol is mg/dL, 130 mg/dL=3.36 mM/L.
P value was calculated by McNemar test.
Fasting
Number 
Concentration of
non-HDL-C
P
value
Non 
HDL-C<130
Number (%)
Non 
HDL-C≥130
Number (%)
PP 2 hr
<130 29 25 (86) 4 (14)
≥130 6 0 (0) 6 (100) 0.125
PP 4 hr
<130 27 25 (93) 2 (7)
≥130 8 0 (0) 8 (100) 0.500
Table 5. Comparison of achieving of target goal between fasting,
post-prandial (PP) 2 and 4 hr non-HDL cholesterol (non-HDL-C)
The unit of HDL cholesterol is mg/dL, 50 mg/dL=1.3 mM/L and 40 mg/dL=1.0 mM/L.
P value was calculated by McNemar test.
HDL, high density lipoprotein; LDL, low-density lipoprotein; NS, not significan.  
Fasting
Number 
P
value LDL-C >50
Number (%)
LDL-C ≤50
Number (%)
Fasting
Number 
P
value LDL-C >40
Number (%)
LDL-C ≤40
Number (%)
Female
PP 2 hr
HDL-C>50 4 4 (100) 0 (0)
HDL-C≤50 17 0 (0) 17 (100) NS
PP 4 hr
HDL-C>50 4 4 (100) 0 (0)
HDL-C≤50 17 0 (0) 17 (100) NS
Male
PP 2 hr
HDL-C>40 5 5 (100) 0 (0)
HDL-C≤40 9 2 (22) 7 (78) NS
PP 4 hr
HDL-C>40 6 6 (100) 0 (0)
HDL-C≤40 8 1 (12) 7 (88) NS
Table 4. Comparison of achieving of target goal between fasting, post-prandial (PP) 2 and 4 hr HDL cholesterol by gender of the subjectsPost-Prandial Lipid Levels in Diabetes with Statin 391
terol levels are not significantly different from fasting values
in type 2 diabetes receiving statin treatment on Korean diet.
For the assessment of achieving target goal in those patients,
the fasting and post-prandial LDL and HDL cholesterol lev-
els do not show significant differences. 
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